Toripalimab plus actinomycin-D for GTN with FIGO score 7
Treatments studied
Part of Cancer, Women’s health & pregnancy clinical trials.
This trial tests a combination of two drugs — toripalimab (an immunotherapy) and actinomycin-D (chemotherapy) — as the first treatment for a specific type of pregnancy-related tumor (GTN) with a FIGO score of 7. The goal is to see if this combination works better than standard treatment.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 60 years old.
- You have been diagnosed with gestational trophoblastic neoplasia (GTN) — a type of pregnancy-related tumor.
- Your FIGO risk score is exactly 7 (your doctor can confirm this).
- You have not had any chemotherapy, radiation, or immunotherapy before.
- Your major organs (like blood, liver, kidneys) are working well enough, based on recent blood tests.
- You are willing to sign a consent form to participate.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of an immunotherapy drug (toripalimab) and a chemotherapy drug (actinomycin-D) as the first treatment for gestational trophoblastic neoplasia (GTN) with a FIGO score of 5-6. It may help patients whose disease is at a moderate risk level.
This Phase 2 trial studies whether combining camrelizumab (an immune medicine) with apatinib (a medicine that blocks blood-vessel growth) can improve treatment for women with high-risk gestational trophoblastic neoplasia (GTN) that is very high-risk, or has returned or resisted chemotherapy. It may help shrink the tumor and reduce the chance it comes back by using two different approaches together.
This trial tests whether using a hysteroscope (a tiny camera) to gently scrape the uterus again, instead of starting chemotherapy right away, can effectively treat a low-risk, pregnancy-related tumor that returns after a molar pregnancy. It's for Chinese women whose disease is still in an early, low-risk stage.
This trial is creating a database for women diagnosed with gestational trophoblastic neoplasia (GTN), which includes tumors that can develop after a molar pregnancy or other pregnancy-related conditions. By joining, you help researchers better understand and improve treatment for these rare tumors.
This trial tests a combination of two immunotherapy drugs (iparomlimab and tuvonralimab) for a rare type of pregnancy-related tumor called intermediate trophoblastic tumor. It may help women whose disease has spread, come back, or is resistant to standard treatment.
This trial tests a new combination of two immunotherapy drugs (LM-108 and Toripalimab) against a standard chemotherapy drug (Paclitaxel) for people with advanced stomach or gastroesophageal junction cancer that has a specific marker called CCR8. It may be an option if you have already tried a first-line therapy and your cancer has progressed or you had side effects from chemotherapy.
Hear when a new Gestational Trophoblastic Neoplasia trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.